167 related articles for article (PubMed ID: 38591109)
21. Role of chromosomal aberrations in clonal diversity and progression of acute myeloid leukemia.
Bochtler T; Fröhling S; Krämer A
Leukemia; 2015 Jun; 29(6):1243-52. PubMed ID: 25673237
[TBL] [Abstract][Full Text] [Related]
22. Comprehensive analysis of mutations and clonal evolution patterns in a cohort of patients with cytogenetically normal acute myeloid leukemia.
Mat Yusoff Y; Ahid F; Abu Seman Z; Abdullah J; Kamaluddin NR; Esa E; Zakaria Z
Mol Cytogenet; 2021 Sep; 14(1):45. PubMed ID: 34560908
[TBL] [Abstract][Full Text] [Related]
23. Acute myeloid leukemia derived from lympho-myeloid clonal hematopoiesis.
Thol F; Klesse S; Köhler L; Gabdoulline R; Kloos A; Liebich A; Wichmann M; Chaturvedi A; Fabisch J; Gaidzik VI; Paschka P; Bullinger L; Bug G; Serve H; Göhring G; Schlegelberger B; Lübbert M; Kirchner H; Wattad M; Kraemer D; Hertenstein B; Heil G; Fiedler W; Krauter J; Schlenk RF; Döhner K; Döhner H; Ganser A; Heuser M
Leukemia; 2017 Jun; 31(6):1286-1295. PubMed ID: 27881874
[TBL] [Abstract][Full Text] [Related]
24. Genetic diversity within leukemia-associated immunophenotype-defined subclones in AML.
Tiso F; Koorenhof-Scheele TN; Huys E; Martens JHA; de Graaf AO; van der Reijden BA; Langemeijer SMC; Preijers FWMB; Kroeze LI; Jansen JH
Ann Hematol; 2022 Mar; 101(3):571-579. PubMed ID: 35024892
[TBL] [Abstract][Full Text] [Related]
25. Leukemia-associated aberrant immunophenotype in patients with acute myeloid leukemia: changes at refractory disease or first relapse and clinicopathological findings.
Cui W; Zhang D; Cunningham MT; Tilzer L
Int J Lab Hematol; 2014 Dec; 36(6):636-49. PubMed ID: 24602197
[TBL] [Abstract][Full Text] [Related]
26. [Clinical and biological prognostic factors in relapsed acute myeloid leukemia patients].
Yébenes-Ramírez M; Serrano J; Martínez-Losada C; Sánchez-García J
Med Clin (Barc); 2016 Sep; 147(5):185-191. PubMed ID: 27374030
[TBL] [Abstract][Full Text] [Related]
27. The role of exosomes in the stemness maintenance and progression of acute myeloid leukemia.
Li Q; Wang M; Liu L
Biochem Pharmacol; 2023 Jun; 212():115539. PubMed ID: 37024061
[TBL] [Abstract][Full Text] [Related]
28. Lineage Switch Between B-Lymphoblastic Leukemia and Acute Myeloid Leukemia Intermediated by "Occult" Myelodysplastic Neoplasm: Two Cases of Adult Patients With Evidence of Genomic Instability and Clonal Selection by Chemotherapy.
Wu B; Jug R; Luedke C; Su P; Rehder C; McCall C; Lagoo AS; Wang E
Am J Clin Pathol; 2017 Aug; 148(2):136-147. PubMed ID: 28898985
[TBL] [Abstract][Full Text] [Related]
29. Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib.
Quek L; David MD; Kennedy A; Metzner M; Amatangelo M; Shih A; Stoilova B; Quivoron C; Heiblig M; Willekens C; Saada V; Alsafadi S; Vijayabaskar MS; Peniket A; Bernard OA; Agresta S; Yen K; MacBeth K; Stein E; Vassiliou GS; Levine R; De Botton S; Thakurta A; Penard-Lacronique V; Vyas P
Nat Med; 2018 Aug; 24(8):1167-1177. PubMed ID: 30013198
[TBL] [Abstract][Full Text] [Related]
30. Detection of acute myeloid leukemic cells in complete remission and in extramedullary sites by clonal analyses.
Schmetzer HM; Wilmanns W; Gerhartz HH
Acta Haematol; 1996; 96(2):83-7. PubMed ID: 8701706
[TBL] [Abstract][Full Text] [Related]
31. Cytogenetic clonal heterogeneity is not an independent prognosis factor in 15-60-year-old AML patients: results on 1291 patients included in the EORTC/GIMEMA AML-10 and AML-12 trials.
Baron F; Stevens-Kroef M; Kicinski M; Meloni G; Muus P; Marie JP; Halkes CJM; Thomas X; Vrhovac R; Specchia G; Lefrere F; Sica S; Mancini M; Venditti A; Hagemeijer A; Becker H; Jansen JH; Amadori S; de Witte T; Willemze R; Suciu S
Ann Hematol; 2018 Oct; 97(10):1785-1795. PubMed ID: 29926156
[TBL] [Abstract][Full Text] [Related]
32. Clonal analysis of progenitor cells by interphase cytogenetics in patients with acute myeloid leukemia and myelodysplasia.
Van Der Lely N; Poddighe P; Wessels J; Hopman A; Geurts van Kessel A; De Witte T
Leukemia; 1995 Jul; 9(7):1167-72. PubMed ID: 7630192
[TBL] [Abstract][Full Text] [Related]
33. Therapeutic targeting in pediatric acute myeloid leukemia with aberrant HOX/MEIS1 expression.
Juul-Dam KL; Shukla NN; Cooper TM; Cuglievan B; Heidenreich O; Kolb EA; Rasouli M; Hasle H; Zwaan CM
Eur J Med Genet; 2023 Dec; 66(12):104869. PubMed ID: 38174649
[TBL] [Abstract][Full Text] [Related]
34. Relapse-Fated Latent Diagnosis Subclones in Acute B Lineage Leukemia Are Drug Tolerant and Possess Distinct Metabolic Programs.
Dobson SM; García-Prat L; Vanner RJ; Wintersinger J; Waanders E; Gu Z; McLeod J; Gan OI; Grandal I; Payne-Turner D; Edmonson MN; Ma X; Fan Y; Voisin V; Chan-Seng-Yue M; Xie SZ; Hosseini M; Abelson S; Gupta P; Rusch M; Shao Y; Olsen SR; Neale G; Chan SM; Bader G; Easton J; Guidos CJ; Danska JS; Zhang J; Minden MD; Morris Q; Mullighan CG; Dick JE
Cancer Discov; 2020 Apr; 10(4):568-587. PubMed ID: 32086311
[TBL] [Abstract][Full Text] [Related]
35. Prediction of relapse of pediatric acute myeloid leukemia by use of multidimensional flow cytometry.
Sievers EL; Lange BJ; Buckley JD; Smith FO; Wells DA; Daigneault-Creech CA; Shults KE; Bernstein ID; Loken MR
J Natl Cancer Inst; 1996 Oct; 88(20):1483-8. PubMed ID: 8841024
[TBL] [Abstract][Full Text] [Related]
36. Pathogenic Mechanisms in Acute Myeloid Leukemia.
Chakraborty S; Park CY
Curr Treat Options Oncol; 2022 Nov; 23(11):1522-1534. PubMed ID: 36190670
[TBL] [Abstract][Full Text] [Related]
37. An Auristatin nanoconjugate targeting CXCR4+ leukemic cells blocks acute myeloid leukemia dissemination.
Pallarès V; Unzueta U; Falgàs A; Sánchez-García L; Serna N; Gallardo A; Morris GA; Alba-Castellón L; Álamo P; Sierra J; Villaverde A; Vázquez E; Casanova I; Mangues R
J Hematol Oncol; 2020 Apr; 13(1):36. PubMed ID: 32295630
[TBL] [Abstract][Full Text] [Related]
38. Development of a Next-generation Sequencing-based Gene Panel Test to Detect Measurable Residual Disease in Acute Myeloid Leukemia.
Kim JJ; Jang JE; Lee HA; Park MR; Kook HW; Lee ST; Choi JR; Min YH; Shin S; Cheong JW
Ann Lab Med; 2023 Jul; 43(4):328-336. PubMed ID: 36843401
[TBL] [Abstract][Full Text] [Related]
39. The bone marrow microenvironment - Home of the leukemic blasts.
Shafat MS; Gnaneswaran B; Bowles KM; Rushworth SA
Blood Rev; 2017 Sep; 31(5):277-286. PubMed ID: 28318761
[TBL] [Abstract][Full Text] [Related]
40. Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia.
McMahon CM; Ferng T; Canaani J; Wang ES; Morrissette JJD; Eastburn DJ; Pellegrino M; Durruthy-Durruthy R; Watt CD; Asthana S; Lasater EA; DeFilippis R; Peretz CAC; McGary LHF; Deihimi S; Logan AC; Luger SM; Shah NP; Carroll M; Smith CC; Perl AE
Cancer Discov; 2019 Aug; 9(8):1050-1063. PubMed ID: 31088841
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
